A 33.9% reduction in pulmonary vascular resistance from a four-patient subgroup is not a number that typically drives pipeline decisions — yet Quince Therapeutics is launching a Phase 2b trial on exactly that foundation. The Phase 2a data for LAM-001, an inhaled rapamycin formulation, in PH-ILD patients refractory to background treprostinil therapy showed a 67.4-meter improvement in six-minute walk distance alongside a 28.8% drop in NT-proBNP at 24 weeks. The entire evaluable PH-ILD cohort transitioned from Functional Class III to Functional Class II. That is a clinically coherent signal across mechanistically distinct endpoints — hemodynamic, functional, and biomarker — which is harder to dismiss than movement in any single measure alone.
The design earns scrutiny before the numbers do. Ten patients enrolled, six evaluable at 24 weeks, four in the PH-ILD subgroup — open-label, no comparator, conducted at four sites. Selection effects and regression to the mean are legitimate concerns in any small refractory cohort. What partially offsets that skepticism is the mechanistic logic: mTOR inhibition targets pulmonary arterial smooth muscle cell proliferation and fibroblast-driven extracellular matrix deposition simultaneously, which is biologically suited to PH-ILD’s dual pathology of vascular remodeling and progressive fibrosis. The inhaled delivery route is designed to concentrate sirolimus in the lung while limiting systemic immunosuppression — the toxicity profile that has historically limited oral rapamycin in chronic pulmonary settings. Tolerability on top of stable treprostinil doses held across the study period, which matters for an add-on strategy.
The regulatory and competitive context sharpens the stakes. PH-ILD has one approved therapy — inhaled treprostinil — and the approval path required a 6MWD improvement that the INCREASE trial delivered at roughly 31 meters. LAM-001’s 67.4-meter signal in patients already on treprostinil, if it replicates, positions this as a combination add-on with a meaningful functional delta over current standard of care. The Phase 2b trial initiating mid-2026 will need to define its comparator arm carefully; an active-controlled design against treprostinil alone would be far more persuasive to regulators than another placebo comparison in this space.
The single number to watch when Phase 2b topline data arrives in Q1 2028 is PVR reduction in the exercise state — not 6MWD. Hemodynamic improvement under exercise load is the endpoint most likely to anchor an accelerated approval discussion and differentiate LAM-001 from symptomatic therapies already on the market.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
